KYinno

About KYinno

KYinno, also known as Kangyuan Bochuang Biotechnology (Beijing) Co., Ltd., is a preclinical contract research organization (CRO) founded in 2017. The company was established by scientists with extensive experience in oncology drug development and operates with a mission to accelerate cancer drug discovery. Headquartered in Beijing, China, KYinno also has a strategic business hub in Boston, USA, to foster international collaborations.

The company provides customized services to biotechnology startups and multinational pharmaceutical corporations to support their drug discovery and development efforts. Its business model is centered on providing a comprehensive suite of preclinical services. These services include in-vitro and in-vivo pharmacology, cell line engineering, therapeutic target identification, and antibody discovery. KYinno serves a global client base of over 1,000 partners. The company's revenue is generated through these fee-for-service offerings.

KYinno's core assets include a vast cell bank with over 3,000 genetically engineered cell lines, which expands by more than 1,000 new lines annually. Key products and platforms feature customized cell lines (such as kinase, immune molecule, and gene-editing lines), multispecific antibody development platforms, a 5,000+ human membrane protein screening panel (MPSA-AB5000), and an AI-based antibody development platform. This infrastructure enables the company to offer specialized services like its Ba/F3 Xenograft Model for studying kinase inhibitors and various solutions for oncology and immunology studies.

Since its founding, the company has seen significant growth, expanding to a 5,000m² laboratory and a team of 130 professionals. The leadership team consists of scientists, strategists, and business innovators. The CEO and Founder is Jinying Ning. KYinno has completed multiple funding rounds, including a Series A round in November 2021, with investors such as Matrix Partners China, Grains Valley Venture Capital, and Hanne Capital.